287 related articles for article (PubMed ID: 15610658)
1. Treatment of follicular non-Hodgkin's lymphoma.
Maloney DG
Curr Hematol Rep; 2005 Jan; 4(1):39-45. PubMed ID: 15610658
[TBL] [Abstract][Full Text] [Related]
2. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma: 2014 update on diagnosis and management.
Freedman A
Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
[TBL] [Abstract][Full Text] [Related]
4. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Brandt L; Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933
[TBL] [Abstract][Full Text] [Related]
5. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Moos M; Schulz R; Martin S; Benner A; Haas R
Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
[TBL] [Abstract][Full Text] [Related]
9. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV
Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561
[TBL] [Abstract][Full Text] [Related]
10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
12. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
13. [Current clinical aspects of follicular lymphoma].
Dreyling M
Ther Umsch; 2010 Oct; 67(10):511-6. PubMed ID: 20886457
[TBL] [Abstract][Full Text] [Related]
14. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; McLaughlin P; White CA; Saleh M; Gordon L; LoBuglio AF; Rosenberg J; Alkuzweny B; Maloney D
Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036
[TBL] [Abstract][Full Text] [Related]
15. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
16. Current treatment and immunotherapy of Hodgkin's lymphoma.
Klimm B; Schnell R; Diehl V; Engert A
Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
[TBL] [Abstract][Full Text] [Related]
17. The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Malig Rep; 2006 Dec; 1(4):220-9. PubMed ID: 20425317
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
19. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
20. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]